Here's Why Novavax Stock Soared on Wednesday

101
18
Favorite

Here's Why Novavax Stock Soared on Wednesday

Motley Fool2021-08-05

Investors could soon have 200 million reasons to celebrate. Novavax jumped over 4% in premarket trading after soaring 18% yesterday. What happened Shares ofNovavax surged 18.7% on Wednesday after ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

101

Report

Comment（18）

bryanckc
·2021-08-06
Omg.. but help to like tho!
Reply
Like
Report
sunshine138
·2021-08-05
The combo will be price riser.When?
Reply
1
Report
JPTL
·2021-08-05
Ok
Reply
2
Report
lewisleeks
·2021-08-05
Great[Miser] [Miser]
Reply
1
Report
Lamborghini1
·2021-08-05
Vacinne for $$$
Reply
4
Report
PorkChopRice
·2021-08-05
Buy buy buy (or buy some more) [開心]
Reply
2
Report
Pixiestars
·2021-08-05
Hopefully will get Fda approval soon.
Reply
4
Report
MIe
·2021-08-05
Upside as non mRNA combined covid cum flu vaccine, with global market share for covid pandemic and endemic #
Reply
3
Report
adriandino
·2021-08-05
Buy buy buy
Reply
5
Report
Fold Replies
- BrOoKe:
  Buy already and sell aLready??
  2021-08-05
  Reply
  Report
Attica88
·2021-08-05
Lqtest
Reply
3
Report
Msx01
·2021-08-05
Pls like
Reply
4
Report
Fold Replies
- cozyli:
  ok
  2021-08-05
  Reply
  Report
SCP03
·2021-08-05
Nice
Reply
3
Report
Fold Replies
- soybeans:
  going up
  2021-08-05
  Reply
  Report
shoude
·2021-08-05
Like and comment
Reply
6
Report
Fold Replies
- cozyli:
  ok
  2021-08-05
  Reply
  Report
- WongKaiqi:
  Ok
  2021-08-05
  Reply
  Report
RyanLJW
·2021-08-05
Like
Reply
4
Report
Fold Replies
- Wenikho:
  Ok
  2021-08-05
  Reply
  Report
alexcsb
·2021-08-05
Well another opportunities
Reply
3
Report
Shyon
·2021-08-05
Hey
Reply
5
Report
Shyon
·2021-08-05
Again?
Reply
2
Report
JoshTay
·2021-08-05
like pls
Reply
4
Report
Fold Replies
- C1238:
  Good
  2021-08-05
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1129515398?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-05 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129515398","market":"us","top_or_hot":-1,"title":"Here's Why Novavax Stock Soared on Wednesday","media":"Motley Fool","content":"<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","article_id":"1129515398","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","pubTimestamp":1628151873,"sourceInfo":null,"weMediaInfo":null,"summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"这就是诺瓦瓦克斯医药股票周三飙升的原因","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":899648597,"gmtCreate":1628182106919,"gmtModify":1703502789713,"author":{"id":"3569900814433914","authorId":"3569900814433914","name":"bryanckc","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Omg.. but help to like tho!","listText":"Omg.. but help to like tho!","text":"Omg.. but help to like tho!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899648597","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899142815,"gmtCreate":1628171222937,"gmtModify":1703502509734,"author":{"id":"3586655655659820","authorId":"3586655655659820","name":"sunshine138","avatar":"https://static.tigerbbs.com/23149c63a63bfeec1572cc27e1322750","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"The combo will be price riser.When?&nbsp;","listText":"The combo will be price riser.When?&nbsp;","text":"The combo will be price riser.When?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899142815","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899355687,"gmtCreate":1628163513749,"gmtModify":1703502354184,"author":{"id":"3585350696038563","authorId":"3585350696038563","name":"JPTL","avatar":"https://static.tigerbbs.com/6f6dde4c2c1d83e8d80141b547948419","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899355687","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899365449,"gmtCreate":1628161607481,"gmtModify":1703502325773,"author":{"id":"4089010444435920","authorId":"4089010444435920","name":"lewisleeks","avatar":"https://static.tigerbbs.com/d39cf835a09bdd21dce8a780b993940c","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"Great[Miser]&nbsp;[Miser]&nbsp;","listText":"Great[Miser]&nbsp;[Miser]&nbsp;","text":"Great[Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899365449","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899310577,"gmtCreate":1628158933799,"gmtModify":1703502285901,"author":{"id":"3578903100181699","authorId":"3578903100181699","name":"Lamborghini1","avatar":"https://static.tigerbbs.com/f8b24a649554234324e1e33be42fc25f","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Vacinne for $$$","listText":"Vacinne for $$$","text":"Vacinne for $$$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899310577","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899310098,"gmtCreate":1628158810514,"gmtModify":1703502284447,"author":{"id":"3555134782523638","authorId":"3555134782523638","name":"PorkChopRice","avatar":"https://static.tigerbbs.com/a98cc137c6872d5c9d28edd7d7e4206a","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Buy buy buy (or buy some more)&nbsp;[開心]&nbsp;","listText":"Buy buy buy (or buy some more)&nbsp;[開心]&nbsp;","text":"Buy buy buy (or buy some more) [開心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899310098","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":899394695,"gmtCreate":1628157803317,"gmtModify":1703502268841,"author":{"id":"3581832720375359","authorId":"3581832720375359","name":"Pixiestars","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Hopefully will get Fda approval soon.","listText":"Hopefully will get Fda approval soon.","text":"Hopefully will get Fda approval soon.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899394695","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899394195,"gmtCreate":1628157765317,"gmtModify":1703502268675,"author":{"id":"3577182936341023","authorId":"3577182936341023","name":"MIe","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":0},"htmlText":"Upside as non mRNA combined covid cum flu vaccine, with global market share&nbsp;for covid&nbsp;pandemic and endemic #&nbsp;","listText":"Upside as non mRNA combined covid cum flu vaccine, with global market share&nbsp;for covid&nbsp;pandemic and endemic #&nbsp;","text":"Upside as non mRNA combined covid cum flu vaccine, with global market share for covid pandemic and endemic #","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899394195","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899971972,"gmtCreate":1628155634196,"gmtModify":1703502231505,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","vip":1,"crmLevel":4,"crmLevelSwitch":1},"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899971972","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5435160,"gmtCreate":1628156214087,"gmtModify":1663231968946,"authorId":4089018853439370,"author":{"id":4089018853439370,"authorId":4089018853439370,"name":"BrOoKe","avatar":"https://static.tigerbbs.com/a8081ab75c39abcb57e6136431300155","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.07","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899971972,"type":1,"supId":0,"prevId":0,"content":"Buy already and sell aLready??","text":"Buy already and sell aLready??","html":"Buy already and sell aLready??"}],"langContent":"EN"},{"id":899957267,"gmtCreate":1628154463059,"gmtModify":1703502211982,"author":{"id":"3577182787260052","authorId":"3577182787260052","name":"Attica88","avatar":"https://static.tigerbbs.com/25f5fb94ec59d52eafaa236c989b1b2b","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Lqtest","listText":"Lqtest","text":"Lqtest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899957267","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899925420,"gmtCreate":1628153515560,"gmtModify":1703502195113,"author":{"id":"3569922361666902","authorId":"3569922361666902","name":"Msx01","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899925420","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5434970,"gmtCreate":1628155001802,"gmtModify":1635159455004,"authorId":3574167470846346,"author":{"id":3574167470846346,"authorId":3574167470846346,"name":"cozyli","avatar":"https://static.tigerbbs.com/509ef7c09d0624801748249c5a3e0117","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899925420,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":899920752,"gmtCreate":1628153050776,"gmtModify":1703502185410,"author":{"id":"3561986763872297","authorId":"3561986763872297","name":"SCP03","avatar":"https://static.tigerbbs.com/2abf42c22b2629cf57b473d657ee801e","vip":1,"crmLevel":6,"crmLevelSwitch":1},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899920752","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5434744,"gmtCreate":1628153522638,"gmtModify":1663231966537,"authorId":3579857427606142,"author":{"id":3579857427606142,"authorId":3579857427606142,"name":"soybeans","avatar":"https://static.tigerbbs.com/c052dba69876e2fe6510af8195f464f3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899920752,"type":1,"supId":0,"prevId":0,"content":"going <u>up</u>","text":"going <u>up</u>","html":"going <u>up</u>"}],"langContent":"EN"},{"id":899964074,"gmtCreate":1628152927298,"gmtModify":1703502181372,"author":{"id":"3587029173183468","authorId":"3587029173183468","name":"shoude","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/899964074","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5434974,"gmtCreate":1628155015650,"gmtModify":1663231965937,"authorId":3574167470846346,"author":{"id":3574167470846346,"authorId":3574167470846346,"name":"cozyli","avatar":"https://static.tigerbbs.com/509ef7c09d0624801748249c5a3e0117","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899964074,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":5434661,"gmtCreate":1628152961162,"gmtModify":1663231965835,"authorId":3581825335913090,"author":{"id":3581825335913090,"authorId":3581825335913090,"name":"WongKaiqi","avatar":"https://static.tigerbbs.com/1be2abd6ee4cc554089e3e3cb741fc3c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899964074,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":899961768,"gmtCreate":1628152591054,"gmtModify":1703502175639,"author":{"id":"4087547182018110","authorId":"4087547182018110","name":"RyanLJW","avatar":"https://static.tigerbbs.com/e396858878cea653fba7a9215fa2ca8f","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899961768","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5434633,"gmtCreate":1628152778030,"gmtModify":1663231964965,"authorId":3583735307988740,"author":{"id":3583735307988740,"authorId":3583735307988740,"name":"Wenikho","avatar":"https://static.tigerbbs.com/48d673eefef20f75808048d78501a48f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899961768,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":899963058,"gmtCreate":1628152418274,"gmtModify":1703502172566,"author":{"id":"3586915072418371","authorId":"3586915072418371","name":"alexcsb","avatar":"https://static.tigerbbs.com/b02b98b9a53bdc70b2b8955a1bb7db4f","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0},"htmlText":"Well another opportunities&nbsp;","listText":"Well another opportunities&nbsp;","text":"Well another opportunities","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899963058","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899960540,"gmtCreate":1628152276180,"gmtModify":1703502170785,"author":{"id":"3581734406950755","authorId":"3581734406950755","name":"Shyon","avatar":"https://static.tigerbbs.com/2a3423cbda71d7a89cd2f2f2d6744330","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Hey","listText":"Hey","text":"Hey","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899960540","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899960838,"gmtCreate":1628152262924,"gmtModify":1703502170138,"author":{"id":"3581734406950755","authorId":"3581734406950755","name":"Shyon","avatar":"https://static.tigerbbs.com/2a3423cbda71d7a89cd2f2f2d6744330","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Again?&nbsp;","listText":"Again?&nbsp;","text":"Again?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/899960838","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":899960369,"gmtCreate":1628152252651,"gmtModify":1703502169977,"author":{"id":"3576201130234151","authorId":"3576201130234151","name":"JoshTay","avatar":"https://static.tigerbbs.com/6221f48f0e5f3a8cbcf13a9982af9401","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899960369","repostId":1129515398,"repostType":4,"repost":{"id":"1129515398","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<blockquote>\n Investors could soon have 200 million reasons to celebrate.\n</blockquote>\n<p><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p>\n<p><b>So what</b></p>\n<p>Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p>\n<p>Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p>\n<p><b>Now what</b></p>\n<p>Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p>\n<p>\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5434614,"gmtCreate":1628152635124,"gmtModify":1631896471058,"authorId":4088591126250580,"author":{"id":4088591126250580,"authorId":4088591126250580,"name":"C1238","avatar":"https://static.tigerbbs.com/1c3415ee92c7e6c23d07e6173daae4d7","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.25","exceedPercentage":"60.60%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":899960369,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":101,"commentSize":18,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}